BioSpace News Archive

Fresenius Medical Care, the world’s leading provider of dialysis products and services, has released an advisory calling for clinical care principles on access to be upheld for patients with advanced chronic kidney disease if a surge in COVID-19 infections overwhelms the available supply of facilities, caregivers and ventilators.

Lipocine Inc., a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the Patent Trial and Appeal Board of the United States Patent and Trademark Office under Rule 36.

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer.

Healthcare Entrepreneur Fred Eshelman, Pharm.D., Appointed Board Chairman Aravive’s Chief Scientific Officer, Gail McIntyre, Ph.D., Appointed CEO Aravive to Host Conference Call Today at 9:00 AM ET HOUSTON, April 09, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced transitions in its board of directors and executive team, effective immediately. Fred Eshelman, Pharm.D., has been unanimously appointed to the

-- Biohaven plans to study intranasal vazegepant, a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist, in pulmonary complications of COVID-19 disease -- Phase 2 study to start within weeks, in collaboration with Thomas Jefferson University and other academic medical institutions -- The clinical trial will assess the potential benefits of CGRP receptor-blockade in mitigating an excessive immune response which in some ca

ReForm Biologics , a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent portfolio with the issuance of U.S. Patent No. 10,610,600 and its first patent in Japan, Japanese Patent No. 6674910. The U.S. patent, entitled “Stabilizing Excipients for Therapeutic Protein Formulations,” provides ReForm exclusive rights to therapeutic pr

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that the United States Patent Office issued U.S. Patent No. 10,597,443 with an expiry of May 2034.

Many women with metastatic hormone receptor-positive breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor.

Bolt Biotherapeutics, Inc.,today announced the appointment of Edith Perez, M.D., as chief medical officer.

Hepatitis C virus infection is of particular concern in patients with chronic kidney disease. There is a much higher prevalence of HCV infection in the CKD/end-stage kidney disease population than is found in the general population.